Loading institutional data...
Loading institutional data...
Held by 455 of 2,417 reporting institutions (98th percentile) — extremely crowded.
Data as of Q3 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading insider activity...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
What the company returns to shareholders — and whether it's covered by cash.
The dividend is comfortably covered — only 31% of free cash flow, leaving room to grow it and fund buybacks. Last year: $1.93B dividends + $1.00B buybacks = $2.93B returned on $6.27B FCF.
9 consecutive years of dividend increases · 7%/yr.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Insufficient data. Current ROIC on all capital: 7%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
Leverage ratios is not shown for an insurer.
Funded by policyholder float, not debt. Reserve adequacy and RBC are the right questions and are not collected yet.
Classified from the filings: SIC code.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $19.71B covers all $18.86B of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2025-12-31 (10-K).
Interest expense isn't separately reported — often netted into “other income (expense), net.” Effective rate ~10.1% on $20.14B of debt. Interest last disclosed in FY2024 (no longer broken out).
Cash of $19.71B fully covers short-term debt of $1.44B.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
No trend data available for this metric.
A reverse discounted cash flow is not shown for an insurer.
Funded by policyholder float, not debt. Reserve adequacy and RBC are the right questions and are not collected yet.
Classified from the filings: SIC code.
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $60.77B 100.0% | $70.41B 100.0% | $53.98B 100.0% | $56.88B 100.0% | $71.25B 100.0% | $57.03B 100.0% | $64.81B 100.0% | $62.99B 100.0% | $59.69B 100.0% | $58.78B 100.0% |
| Selling, General & Admin | $13.01B 21.4% | $13.34B 19.0% | $12.95B 24.0% | $12.58B 22.1% | $13.61B 19.1% | $13.91B 24.4% | $13.42B 20.7% | $11.95B 19.0% | $11.91B 20.0% | $11.78B 20.0% |
| Total Operating Expenses | $35.55B 58.5% | $22.33B 31.7% | $14.55B 27.0% | $3.61B 6.3% | $21.23B 29.8% | $8.89B 15.6% | $5.80B 8.9% | $3.22B 5.1% | — | — |
| Interest Expense | — | $2.03B 2.9% | $1.76B 3.3% | $1.60B 2.8% | $1.48B 2.1% | $1.56B 2.7% | $1.55B 2.4% | $1.42B 2.3% | $1.33B 2.2% | $1.32B 2.2% |
| Pretax Income | $4.66B 7.7% | $3.21B 4.6% | $3.07B 5.7% | -$1.89B -3.3% | $10.84B 15.2% | -$323.0M -0.6% | $5.08B 7.8% | $4.83B 7.7% | $6.49B 10.9% | $5.71B 9.7% |
| Income Tax Expense | $1.05B 1.7% | $507.0M 0.7% | $613.0M 1.1% | -$279.0M -0.5% | $2.00B 2.8% | -$81.0M -0.1% | $947.0M 1.5% | $822.0M 1.3% | -$1.44B -2.4% | $1.33B 2.3% |
| Net Income | $3.58B 5.9% | $2.73B 3.9% | $2.49B 4.6% | -$1.65B -2.9% | $8.87B 12.4% | -$374.0M -0.7% | $4.19B 6.5% | $4.07B 6.5% | $7.86B 13.2% | $4.37B 7.4% |
| Per Share | ||||||||||
| EPS (Basic) | $10.05 | $7.54 | $6.76 | -$4.49 | $22.56 | -$1.00 | $10.23 | $9.64 | $18.19 | $9.85 |
| EPS (Diluted) | $9.99 | $7.50 | $6.74 | -$4.49 | $22.40 | -$1.00 | $10.11 | $9.50 | $17.86 | $9.71 |
| Weighted Avg Shares (Basic) | 351.8M | 357.5M | 363.5M | 372.3M | 387.2M | 395.8M | 404.8M | 417.6M | 427.0M | 438.2M |
| Weighted Avg Shares (Diluted) | 353.7M | 359.3M | 364.6M | 372.3M | 390.1M | 395.8M | 410.9M | 426.2M | 436.0M | 446.6M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Last reported position per insider, carried forward. Steps can be a holding disclosed for the first time rather than a trade.
| Date | Insider | What it was | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-09-10 | 3 co-filers Group filing | Grant | 214 | $118.48 | — |
| 2026-09-10 | 2 co-filers Group filing | Grant | 20 | $118.48 | — |
| 2026-09-10 | 2 co-filers Group filing | Grant | 21 | $118.48 | — |
| 2026-09-10 | Mannen Maryann T. Director | Grant | 21 | $118.48 | — |
| 2026-09-10 | 3 co-filers Group filing | Grant | 115 | $118.48 | — |
| 2026-09-10 | 2 co-filers Group filing | Grant | 37 | $118.48 | — |
| 2026-09-10 | Sullivan Andrew F Chief Executive Officer | Grant | 143 | $118.48 | — |
| 2026-09-10 | 3 co-filers Group filing | Grant | 180 | $118.48 | — |
| 2026-09-10 | 3 co-filers Group filing | Grant | 161 | $118.48 | — |
| 2026-09-10 | 2 co-filers Group filing | Grant | 513 | $118.48 | — |
| 2026-09-10 | 3 co-filers Group filing | Grant | 155 | $118.48 | — |
| 2026-09-10 | 3 co-filers Group filing | Grant | 336 | $118.48 | — |
| 2026-09-10 | 2 co-filers Group filing | Grant | 21 | $118.48 | — |
| 2026-09-10 | 2 co-filers Group filing | Grant | 21 | $118.48 | — |
| 2026-09-10 | 2 co-filers Group filing | Grant | 21 | $118.48 | — |
| 2026-09-10 | 2 co-filers Group filing | Grant | 21 | $118.48 | — |
| 2026-09-10 | 3 co-filers Group filing | Grant | 49 | $118.48 | — |
| 2026-09-10 | 3 co-filers Group filing | Grant | 84 | $118.48 | — |
| 2026-09-10 | 3 co-filers Group filing | Grant | 21 | $118.48 | — |
| 2026-09-10 | 3 co-filers Group filing | Grant | 151 | $118.48 | — |
| 2026-09-10 | 3 co-filers Group filing | Grant | 21 | $118.48 | — |
| 2026-09-10 | 3 co-filers Group filing | Grant | 21 | $118.48 | — |
| 2026-09-10 | 3 co-filers Group filing | Grant | 21 | $118.48 | — |
| 2026-09-10 | 3 co-filers Group filing | Grant | 21 | $118.48 | — |
| 2026-09-10 | 3 co-filers Group filing | Grant | 21 | $118.48 | — |
| 2026-08-31 | 3 co-filers Senior Vice President | Option exercise | 353 | $0.00 | $0 |
| 2026-08-31 | 3 co-filers Senior Vice President | Tax withholding | 115 | $117.60 | $14k |
| 2026-08-31 | 3 co-filers Senior Vice President | Option exercise | 353 | $0.00 | — |
| 2026-08-14 | Kappler Ann M EVP and General Counsel | Open-market sale | 7,652 | $125.01 | $957k |
| 2026-06-11 | 3 co-filers Group filing | Grant | 197 | $106.51 | — |
| 2026-06-11 | Mannen Maryann T. Director | Grant | 23 | $106.51 | — |
| 2026-06-11 | 3 co-filers Group filing | Grant | 126 | $106.51 | — |
| 2026-06-11 | 2 co-filers Group filing | Grant | 23 | $106.51 | — |
| 2026-06-11 | 2 co-filers Group filing | Grant | 563 | $106.51 | — |
| 2026-06-11 | 2 co-filers Group filing | Grant | 22 | $106.51 | — |
| 2026-06-11 | Sullivan Andrew F Chief Executive Officer | Grant | 158 | $106.51 | — |
| 2026-06-11 | 3 co-filers Group filing | Grant | 177 | $106.51 | — |
| 2026-06-11 | 3 co-filers Group filing | Grant | 170 | $106.51 | — |
| 2026-06-11 | 3 co-filers Group filing | Grant | 236 | $106.51 | — |
| 2026-06-11 | 2 co-filers Group filing | Grant | 41 | $106.51 | — |
Every row is classified by what it MEANT, not by its SEC code. A code is not a meaning: code P (“purchase”) also covers dividend reinvestment and employee stock purchase plans, and code S (“sale”) also covers 10b5-1 plan sales scheduled months earlier and option exercises sold the same day.
Across 30 days of all filings, $5.08bn of insider selling contained $3.50bn of plan sales and $0.46bn of exercise-and-sell. Only 29% was discretionary. Reading an unclassified feed badly overstates how much insiders decided.
Buys and sales are counted separately and never netted. They are different decisions by different people; a company where one officer bought while another sold is not “neutral”.
The holding line carries each insider's last reported position forward, so it shows the total held rather than a sawtooth of whoever traded that day. It covers only insiders who filed in the window.
“Filed late” counts calendar days past the two-business-day deadline with five days' grace, so a Thursday or Friday trade crossing a weekend is never flagged. It describes the company's filing discipline, not the trade.
Insider activity is descriptive. Nothing here is investment advice.
No current price collected.
Where each multiple sits in its own 14-yr range
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
ROE 11% against ROIC 7% — 4% of the return on equity comes from leverage and buybacks rather than from the operating business.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
Operating leverage needs meaningful revenue change.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| SG&A | 19.0 | 20.7 | 24.4 | 19.1 | 22.1 | 24.0 | 19.0 | 21.4 |
| Income Tax | 1.3 | 1.5 | -0.1 | 2.8 | -0.5 | 1.1 | 0.7 | 1.7 |
| Net Income | 6.5 | 6.5 | -0.7 | 12.4 | -2.9 | 4.6 | 3.9 | 5.9 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on PRU: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
No positive operating income in the last three years, so there is no return on capital to compare against its cost.
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2016 | not reported | not reported | 7.4% |
| FY2017 | not reported | not reported | 13.2% |
| FY2018 | not reported | not reported | 6.5% |
| FY2019 | not reported | not reported | 6.5% |
| FY2020 | not reported | not reported | -0.7% |
| FY2021 | not reported | not reported | 12.4% |
| FY2022 | not reported | not reported | -2.9% |
| FY2023 | not reported | not reported | 4.6% |
| FY2024 | not reported | not reported | 3.9% |
| FY2025 | not reported | not reported | 5.9% |
Leverage and buybacks account for 4 points of the 11% return on equity in FY2025. The business earns 7% on the capital it employs; the rest is balance sheet.
ROE is on average equity; ROIC is NOPAT over average invested capital (debt plus equity less excess cash). The gap is not a single adjustment.
No material counter-signal in the checked set: ROIC vs WACC spread, 5-year spread history, gross margin trend, operating margin trend, net margin against 3 years ago, revenue growth, ROIC ex-goodwill gap.
Missing from our data, so excluded from this answer: beta, market_cap.
Converts 2.66x of reported profit into free cash flow over 5 years, with accruals negative.
The cash conversion cycle could not be computed — receivables, inventory or cost of revenue is not reported — so the earliest accrual warning is not part of this verdict.
Leverage is not measurable this way for a insurer.
Ladder as of 2025-12-31 (10-K); cash from the 2025-12-31 balance sheet; FCF from FY2025.
Balance sheet at 2025-12-31. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
Funded by policyholder float, not debt. Reserve adequacy and RBC are the right questions and are not collected yet.
Missing from our data, so excluded from this answer: capital adequacy metrics for this archetype.
No current price or share count, so the market's assumption cannot be solved for.
No material counter-signal in the checked set: reverse-DCF implied growth, historical FCF CAGR, per-year FCF growth distribution, reporting-basis breaks, discount rate used, free-cash-flow basis (stock comp charged?).
Missing from our data, so excluded from this answer: market_cap.
| Step | Amount | Running total |
|---|---|---|
| Net income | $3.58B | $3.58B |
| Share-based comp | $257M | $3.83B |
| Other non-cash & working capital | $2.44B | $6.27B |
| Operating cash flow | $6.27B | $6.27B |
| Capex | $0 | $6.27B |
| Free cash flow | $6.27B | $6.27B |
| FCF after SBC | $6.01B | $6.01B |
| Fiscal year | Revenue growth | Receivables growth | Gap |
|---|---|---|---|
| FY2020 | -12.0% | not reported | not reported |
| FY2021 | 24.9% | not reported | not reported |
| FY2022 | -20.2% | not reported | not reported |
| FY2023 | -5.1% | not reported | not reported |
| FY2024 | 30.4% | not reported | not reported |
| FY2025 | -13.7% | not reported | not reported |
| Fiscal year | Accruals / assets |
|---|---|
| FY2019 | -1.7 percent |
| FY2020 | -0.9 percent |
| FY2021 | -0.1 percent |
| FY2022 | -1.0 percent |
| FY2023 | -0.6 percent |
| FY2024 | -0.8 percent |
| FY2025 | -0.3 percent |
Below the line, the asset base is being consumed faster than it is replaced.
Below the line for 2 consecutive years to the latest.
Depreciation here includes amortisation of acquired intangibles — goodwill written down over time, customer lists, acquired technology. Capex does not replace those and is not meant to, so an acquisitive or asset-light company sits below 1.0 permanently and correctly. The signal is cleanest for capital-intensive businesses, where the two measure the same physical base. For that reason this informs the earnings-quality verdict but never caps it.
SBC is added back inside operating cash flow, so reported free cash flow treats shares issued to employees as free. Percent of revenue says how expensive the payroll is; percent of operating cash flow says how much of the cash exists only because the charge was added back. The buyback offset is buybacks over SBC — below 1.0 the repurchase does not cover the shares issued.
Figures are the latest fiscal year (FY2025) from the company's own filings, not a trailing-twelve-month window — Q2 reads fiscal years throughout so the cash-conversion ratios and these share one basis. A blank is a line the filer did not report; it is never read as zero.